Education
About Us
Working with TipRanks
Follow Us
Syra Health Corp. Class A (SYRA)
OTHER OTC:SYRA
Top Page
Syra Health Corp. Class A
(OTC:SYRA)
Rating:49Neutral
Price Target:
$0.00
▼(-100.00% Downside)
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.18M
Dividend YieldN/A
Average Volume (3M)25.18K
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth14.07%
EPS Growth76.85%
CountryUS
Employees57
SectorHealthcare
Sector Strength51
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding11,339,169
10 Day Avg. Volume52,812
30 Day Avg. Volume25,176
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.76
Enterprise Value/Revenue-0.11
Enterprise Value/Gross Profit-0.36
Enterprise Value/Ebitda0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Syra Health Corp. Class A Business Overview & Revenue Model
Company DescriptionSyra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
How the Company Makes MoneySyra Health Corp. generates revenue primarily through its digital health platforms, healthcare consultancy services, and data management solutions. These platforms and services are offered to healthcare providers, hospitals, and other medical institutions seeking to improve their operational efficiencies and patient outcomes. Revenue streams include subscription fees for digital health platforms, consulting fees for bespoke healthcare solutions, and contractual agreements for data analytics services. Key partnerships with medical institutions and technology firms also contribute to the company's earnings by expanding its market reach and enhancing its service offerings. Additionally, Syra Health may engage in strategic alliances and collaborations to further diversify its income through joint ventures and co-developed health technology products.
Syra Health Corp. Class A Earnings Call Summary
Earnings Call Date:Aug 12, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.Q1-2025 Updates
Positive Updates
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Population Health Business Expansion
Population Health revenue reached $1.2 million, a 261% year-over-year increase, contributing 65% of total revenue compared to 19% in Q1 2024.
Gross Margin Improvement
Gross margin expanded by 14.6 percentage points to 31.7%, driven by increased contributions from Population Health and milestone-driven projects.
Operational Efficiency
Operating expenses declined by 39% year-over-year, leading to a significant improvement in net loss, which reduced over two-thirds to $472,000 from $1.4 million in Q1 2024.
New Contracts and Extensions
Syra Health signed a new year-long contract with a major insurance provider and secured a contract extension with the National Healthcare Organization valued at $660,000.
Negative Updates
Delisting from NASDAQ
The company announced a strategic decision to voluntarily delist from the NASDAQ capital market to reduce costs and strengthen core fundamentals.
Federal Contract Delays
Federal-level changes have led to project pauses, reinstatements, and cuts, impacting revenue and cash flow due to delays in new contracts and cancellations.
Healthcare Workforce Revenue Decline
Revenue from the Healthcare Workforce unit declined to $655,000 from $1.4 million in Q1 2024, as part of a strategic shift away from lower-margin contracts.
Withdrawing Financial Guidance
Due to ongoing changes in the healthcare industry and funding impacts, Syra Health withdrew its previously issued guidance for revenue growth and profitability.
Company Guidance
During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.Syra Health Corp. Class A Financial Statement Overview
Summary
Syra Health shows strong revenue growth but faces significant profitability and cash flow challenges. The balance sheet indicates low leverage, but historical negative equity poses risks. Operational efficiencies and cash generation need improvement for sustainable financial health.Income Statement
The company has shown a revenue growth rate of 44.7% from 2023 to 2024, indicating strong top-line growth. However, the net profit margin is negative at -47.1% in 2024, showing ongoing profitability challenges. The gross profit margin improved slightly to 20.7%, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.45
Neutral
Balance Sheet
The debt-to-equity ratio is relatively low at 0.16, indicating conservative leverage. However, the return on equity is negative due to net losses. The equity ratio is 78.3%, suggesting a strong capital structure. Despite these strengths, the negative equity in previous years highlights potential financial instability.55
Neutral
Cash Flow
The free cash flow is negative and deteriorated by 6.1% from 2023 to 2024, indicating cash flow challenges. The operating cash flow to net income ratio is not favorable as both are negative, indicating inefficiencies in converting earnings into cash flows.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.06M | 7.98M | 5.52M | 5.62M | 1.41M | 0.00 |
| Gross Profit | 2.47M | 1.65M | 1.41M | 1.06M | 430.35K | 0.00 |
| EBITDA | -1.41M | -3.68M | -2.84M | -2.07M | -3.07K | -4.27K |
| Net Income | -1.46M | -3.76M | -2.94M | -2.12M | -3.28K | -4.27K |
Balance Sheet | ||||||
| Total Assets | 3.47M | 3.68M | 4.92M | 2.32M | 536.89K | 3.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.31M | 2.40M | 3.28M | 3.34K | 100.01K | 3.00K |
| Total Debt | 108.88K | 452.08K | 248.10K | 934.84K | 342.86K | 3.00K |
| Total Liabilities | 1.06M | 800.76K | 910.07K | 1.61M | 544.04K | 7.17K |
| Stockholders Equity | 2.41M | 2.88M | 4.01M | 710.10K | -7.15K | -4.17K |
Cash Flow | ||||||
| Free Cash Flow | -542.27K | -2.94M | -2.77M | -2.37M | -94.49K | 0.00 |
| Operating Cash Flow | -542.27K | -2.93M | -2.76M | -2.24M | -88.20K | 0.00 |
| Investing Cash Flow | 0.00 | -11.11K | -15.25K | -121.26K | -6.29K | 0.00 |
| Financing Cash Flow | 1.25M | 2.06M | 6.05M | 2.27M | 191.50K | 36.00K |
Syra Health Corp. Class A Technical Analysis
Positive
0.09
Price Trends
0.09
Positive
0.09
Positive
0.24
Negative
Market Momentum
<0.01
Negative
55.76
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 46 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syra Health Corp. Class A Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $16.28M | 11.72 | -9.49% | ― | 26.61% | -156.30% | |
51 Neutral | $7.93B | -0.32 | -43.43% | 2.21% | 22.30% | -1.88% | |
50 Neutral | $34.81M | 380.00 | 93.38% | 8.91% | 1.10% | 98.13% | |
49 Neutral | $1.18M | ― | -64.70% | ― | 14.07% | 76.85% | |
46 Neutral | $63.11M | ― | -138.17% | ― | 4.20% | -54.16% | |
40 Underperform | $4.73M | ― | -951.52% | ― | -0.70% | -2.38% | |
39 Underperform | $25.07M | ― | 14.03% | ― | -29.82% | -2.57% |
* Healthcare Sector Average
Performance Comparison
SYRA
Syra Health Corp. Class A
0.09
-0.79
-89.77%
AMS
American Shared Hospital Services
2.47
-0.60
-19.54%
CCM
Concord Medical Services
5.64
0.40
7.63%
MODVQ
ModivCare
0.36
-29.64
-98.80%
CCEL
Cryo-Cell International
4.49
-1.20
-21.09%
PIII
P3 Health Partners
8.79
-16.30
-64.97%
Syra Health Corp. Class A Corporate Events
Executive/Board Changes
Syra Health Corp. Appoints Radhika Mereddy to Board
Neutral
Aug 15, 2025
On August 13, 2025, Syra Health Corp. appointed Radhika Mereddy to its Board of Directors. Ms. Mereddy’s compensation will align with that of other non-employee directors, and there are no special arrangements or related party transactions influencing her appointment, despite her being a principal stockholder in several companies.
Executive/Board Changes
Syra Health Appoints Priya Prasad as Interim CEO
Neutral
Jun 17, 2025
On June 13, 2025, Syra Health Corp.’s Board of Directors terminated the employment agreement with CEO Deepika Vuppalanchi, initially established on April 5, 2021. Subsequently, on June 16, 2025, Priya Prasad, the company’s CFO and COO, was appointed as interim CEO, indicating a significant leadership transition within the company.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.